Net (Loss) Income per Common Share

3 Months Ended

Jun. 30, 2025

Net (Loss) Income per Common Share [Abstract]

Note 14—Net (Loss) Income per Common Share

Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net (loss) income attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period.

For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three months ended June 30, 2025 all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss from continuing operations.

As of June 30, 2025 and 2024, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net (loss) income per common share:

	June 30, 2025		June 30, 2024
Stock options and performance stock options		135,593,216		54,648,258
Restricted stock units and performance stock units (non-vested)		53,111,118		5,422,465
March 2020 CVARs⁽¹⁾		17,548,368		17,548,368
November 2021 CVARs (non-vested)		—		200,722
Restricted common stock (non-vested)		—		255,911
Earn-Out Shares (non-vested)		3,080,387		3,080,387
Other stock based awards and instruments issued		4,485,265		3,924,305

⁽¹⁾Refer to Note 9, “Share-Based Compensation and Other Compensation Plans” for details regarding settlement of CVARs.